Drug intelligence / Profile preview

PG016

Development stage: Preclinical
Lead developer: PersonGen Anke Cellular Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

PG016 is an experimental **in vivo chimeric antigen receptor (CAR) T-cell therapy** being developed by **PersonGen-Anke Cellular Therapeutics** for the treatment of **solid tumors**. Unlike traditional CAR-T therapies that require the extraction, modification, and re-infusion of a patient's cells (ex vivo), PG016 is designed to genetically engineer T cells directly within the patient's body to express CARs. This approach aims to simplify the manufacturing process and increase the accessibility of cell therapies. The specific molecular target for PG016 has not been disclosed by the developer. As of late 2025, the program is in the **preclinical** stage of development.

Beyond the preview

Go deeper on PG016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PG016.

Explore the full profile